Pulmonx Corporation (LUNG) Free Cash Flow
Pulmonx Corporation (LUNG) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2020-12-31 | -$31.51M |
| 2021-12-31 | -$45.06M |
| 2022-12-31 | -$46.40M |
| 2023-12-31 | -$38.42M |
| 2024-12-31 | -$32.95M |
| 2025-12-31 | -$32.85M |
How LUNG compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| ATOS | Atossa Therapeutics Inc. | -$29.79M |
| VERU | Veru Inc. | -$30.04M |
| ENTA | Enanta Pharmaceuticals Inc. | -$32.17M |
| CRVS | Corvus Pharmaceuticals Inc. | -$32.97M |
| TENX | — | -$35.80M |
These are five companies in the same sector as LUNG with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Pulmonx Corporation Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("LUNG", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | LUNG | $2.42 | -3.20% | 0.27M |
| 3 | ||||
| 4 | ||||
| 5 |